Dot gov

Official websites use the Texas HHS logo.
The Texas HHS logo means this is an official website of Texas Health and Human Services.

HTTPS

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

5. References

  1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc; 2024. Available at: http://www.clinicalpharmacology.com. Accessed May 28th, 2024.
  2. Rifaximin (Xifaxan) package insert. Salix Pharmaceuticals, October 2023.
  3. DuPont HL, Ericsson CD, Mathewson JJ, et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. Digestion. 1998;59:708-14.
  4. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med. 2005;142:805-12.
  5. DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of travelers’ diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001;33:1807-15.
  6. Pakyz AL. Rifaximin: a new treatment for travelers’ diarrhea. Ann Pharmacother. 2005;39:284-9.
  7. DuPont HL. Travellers’ diarrhoea: contemporary approaches to therapy and prevention. Drugs.  2006;66:303-14.
  8. Okhuysen PC. Current concepts in travelers' diarrhea: epidemiology, antimicrobial resistance and treatment. Curr Opin Infect Dis. 2005;18:522-6.
  9. Layer P, Andresen V. Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea. Aliment Pharmacol Ther. 2010;31(11):1155-64.
  10. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071-81.
  11. Pimentel M, Lembo A, Chey WD, et al. for the TARGET Study Group.  Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22-32.
  12. Shayto RH, Abou Mrad R, Sharara AI. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol. 2016; 22(29): 6638-51.
  13. Gionchetti P, Rizzello F, Ferrieri A, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci. 1999;44:1220-1.
  14. Prantera C, Lochs H, Campieri M, et al. Antibiotic treatment of Crohn’s disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther. 2006;23:1117-25.
  15. Adachi JA, DuPont HL Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis. 2006;42:541-7.
  16. Taylor DN, McKenzie R, Durbin A, et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis. 2006;42:1283-8.
  17. Huang DB, DuPont HL. Rifaximin – a novel antimicrobial for enteric infections. J Infect. 2005;50(2):97-106.  
  18. Taylor DN, Bourgeois AL, Ericsson CD, et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers’ diarrhea. Am J Trop Med Hyg. 2006;74:1060-6.
  19. Frisari L, Viggiano V, Pelagalli M. An open, controlled study of two non-absorbable antibiotics for the oral treatment of paediatric infectious diarrhea.  Curr Med Res Opin. 1997;14:39-45.
  20. Vinci M, Gatto A, Giglio A, et al. Double-blind clinical trial on infectious diarrhea therapy: rifaximin versus placebo. Curr Ther Res. 1984;36:92-9.
  21. Paik YH, Lee KS, Han KH, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.  Yonsei Med J. 2005;46:399-407.
  22. Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003;38:51-8.
  23. Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomized trial. Curr Med Res Opin. 1997;13:593-601.
  24. Phongsamran PV, Kim JW, Cupo Abbott J, Rosenblatt A. Pharmacotherapy for hepatic encephalopathy. Drugs. 2010;70(9):1131-48.
  25. Vlachogiannakos J, Viazis N, Vasianopoulou P, et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013;28:450-5.
  26. Hong KS, Kim JS. Rifaximin for the treatment of acute infectious diarrhea. Therap Adv Gastroenterol. 2011;4(4):227-235.
  27. Connor, A. Travelers’ diarrhea, Chapter 2, Yellow Book: Travelers’ Health. Centers for Disease Control and Prevention. 2020.